Liposomes Patents (Class 424/450)
-
Patent number: 10744197Abstract: The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.Type: GrantFiled: November 28, 2016Date of Patent: August 18, 2020Assignee: NITTO DENKO CORPORATIONInventors: Takuya Shishido, Daisuke Asari, Eiji Kiyotoh, Kyohei Matsushita, Wenjing Li, Masahiro Fukasaka, Katsuyuki Okubo, Mitsuhiko Hori
-
Patent number: 10736846Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.Type: GrantFiled: June 12, 2019Date of Patent: August 11, 2020Assignees: TAIWAN LIPOSOME CO., LTD., TCL BIOPHARMACEUTICALS, INC.Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
-
Patent number: 10736952Abstract: The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (VLP), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents. Preferably such vaccines generate a therapeutically effective immune response to all pathogenic strains and/or serotypes of the same infectious agent. In particular, the invention is directed to methods and compositions for the cost efficient administration of a vaccine to a patient in need thereof exposing the patient's immune system to only the immunogenic components that are likely to be beneficial for the generation of a protective immunological response, both efficacy and safety are increased and cost effectively.Type: GrantFiled: December 7, 2018Date of Patent: August 11, 2020Assignee: Inventprise, LLCInventor: Subhash V. Kapre
-
Patent number: 10736844Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an attenuated or inactivated virus in combination with a non-ionic surfactant vesicle (NISV).Type: GrantFiled: January 13, 2012Date of Patent: August 11, 2020Assignee: VARIATION BIOTECHNOLOGIES INC.Inventors: David E. Anderson, Tanvir Ahmed, Jasminka Bozic, Marc Kirchmeier
-
Patent number: 10729651Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: GrantFiled: March 6, 2013Date of Patent: August 4, 2020Assignee: Pacira Pharmaceuticals, Inc.Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
-
Patent number: 10729690Abstract: Inappropriate activation of innate immune responses in nematode intestinal epithelial cells underlies the pathophysiology of some inflammatory disorders. Immunostimulatory xenobiotics are known to protect nematodes from bacterial infection (e.g., Pseudomonas aeruginosa). Conversely, these same xenobiotics are toxic to uninfected nematodes. These xenobiotics were subjected to a forward genetic screen in uninfected nematodes to identify nematode mutants that were resistant to the deleterious effects of these xenobiotics. These resistant nematode strains contained hypomorphic mutations in each of the known components of the p38 MAP kinase cassette (tir-1, nsy-1, sek-1 and pmk-1), demonstrating that hyperstimulation of p38 MAPK innate immune responses may be responsible for the induced toxicity. A second genetic screen using dominant activators of the p38 MAPK pathway identified a single allele that had a gain-of-function (gf) mutation in nsy-1, the MAP kinase kinase kinase that acts upstream of p38 MAPK pmk-1.Type: GrantFiled: January 12, 2017Date of Patent: August 4, 2020Assignee: University of MassachusettsInventor: Read Pukkila-Worley
-
Patent number: 10722464Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.Type: GrantFiled: July 27, 2018Date of Patent: July 28, 2020Assignee: Celator Pharmaceuticals, Inc.Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
-
Patent number: 10722570Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an amino acid.Type: GrantFiled: November 28, 2016Date of Patent: July 28, 2020Assignee: NITTO DENKO CORPORATIONInventors: Eiji Kiyotoh, Mitsuhiko Hori, Daisuke Asari, Katsuyuki Okubo, Takuya Shishido, Masahiro Fukasaka, Kyohei Matsushita
-
Patent number: 10722508Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.Type: GrantFiled: February 14, 2018Date of Patent: July 28, 2020Assignee: Ipsen Biopharm Ltd.Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
-
Patent number: 10722545Abstract: The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.Type: GrantFiled: January 1, 2018Date of Patent: July 28, 2020Inventor: Alexander Kariman
-
Patent number: 10717777Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.Type: GrantFiled: December 16, 2016Date of Patent: July 21, 2020Assignee: The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterInventors: Frans J. Walther, Alan J. Waring, Larry M. Gordon
-
Patent number: 10716860Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.Type: GrantFiled: November 13, 2017Date of Patent: July 21, 2020Assignees: Matinas BioPharma Nanotechnologies, Inc., Rutgers, The State University of New JerseyInventors: Raphael Mannino, Ruying Lu
-
Patent number: 10709673Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: September 13, 2019Date of Patent: July 14, 2020Assignee: GW Research LimitedInventor: Geoffrey Guy
-
Patent number: 10709665Abstract: Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.Type: GrantFiled: November 17, 2017Date of Patent: July 14, 2020Assignee: Pacira Pharmaceuticals, Inc.Inventors: Louie Daniel Garcia, Stephanie Kurz, Soroush Ardekani, Kathleen Dunne Albright Los, Katherine Stone, Ernest G. Schutt, Vladimir Kharitonov
-
Patent number: 10702245Abstract: The present invention provides a method of detecting microbubbles in a vessel of an affected part, comprising aggregates the microbubbles, acquiring phase-contrast magnetic resonance images and analyzing the phase-contrast magnetic resonance images. Thus, we can detect or monitor the size and location of the microbubbles in vessels of any part of body.Type: GrantFiled: May 4, 2017Date of Patent: July 7, 2020Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Hsu-Hsia Peng, Che-Wei Wu
-
Patent number: 10702581Abstract: The present invention relates to a method for the mass-production of exosome comprising a cargo protein, a vector for preparing the exosome, exosome including a cargo protein prepared by the method, and a method for loading the cargo protein to cytosol by using the exosome prepared thereby. According to the method for preparing an exosome comprising a cargo protein provided by the present invention, the exosome loaded with a cargo protein can be produced with a high yield, so that it can be used broadly in the treatment of disease using the exosome.Type: GrantFiled: November 3, 2017Date of Patent: July 7, 2020Assignee: ILIAS BIOLOGICS INC.Inventors: Chulhee Choi, Nambin Yim, Won Do Heo, Seung-Wook Ryu, Hojun Choi, Kyungsun Choi
-
Patent number: 10703823Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.Type: GrantFiled: July 26, 2018Date of Patent: July 7, 2020Assignee: YALE UNIVERSITYInventors: David Spiegel, Ryan Murelli, Andrew Zhang
-
Patent number: 10695378Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.Type: GrantFiled: June 4, 2018Date of Patent: June 30, 2020Assignee: Duke UniversityInventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
-
Patent number: 10695425Abstract: Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes.Type: GrantFiled: April 20, 2018Date of Patent: June 30, 2020Assignee: Biocrine ABInventor: Per-Olof Berggren
-
Patent number: 10695290Abstract: A non-irritation, non-blurring, photostable ophthalmic sunscreen composition contains at least one of the following: bemotrizinol; bisoctrizole; tris-biphenyl triazine; and/or octyl methoxycinnamate. A liquid vehicle base is then a remainder of the solution by weight. The composition is an artificial tear formulation or an ophthalmic suspension or ointment. The composition may include at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.Type: GrantFiled: July 12, 2017Date of Patent: June 30, 2020Assignee: A. EBBIE SOROUDI, M.D., M.S., A PROFESSIONAL MEDICAL CORPORATIONInventor: A. Ebbie Soroudi
-
Patent number: 10695444Abstract: Provided herein are compounds of Formula (I), and salts thereof, wherein each instance of RL is independently optionally substituted C6-C40 alkenyl. Further provided are compositions comprising a compound of Formula (I) and an agent. Further provided are methods and kits using the compositions for delivering an agent to a subject or cell and for treating and/or preventing a range of diseases. Further provided are methods of preparing compounds of Formula (I) and precursors thereof.Type: GrantFiled: February 6, 2019Date of Patent: June 30, 2020Assignee: Massachusetts Institute of TechnologyInventors: Daniel Griffith Anderson, Joseph R. Dorkin, Owen Shea Fenton, Kevin John Kauffman, Rebecca L. McClellan
-
Patent number: 10695424Abstract: The present invention provides compositions, methods and processes for the maturation of submicron liposome compositions comprising a lipid, a sterol, and a saponin.Type: GrantFiled: December 5, 2017Date of Patent: June 30, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Cara, Veronique Monique Roberte Henderickx, Vinciane Martha De Cupere, Carine Berthe Ghislaine De Kesel
-
Patent number: 10687544Abstract: A feed additive composition includes a protective agent, lecithin, an acidic or neutral amino acid, and water. A method of producing a feed additive composition includes preparing a molten mixture of a protective agent, lecithin, and an acidic or neutral amino acid, and immersing the molten mixture in water or an aqueous liquid to obtain a solidified mixture. Feed additives may be obtained by such method. The protective agent may include a hydrogenated vegetable oil or hydrogenated animal oil having a melting point of higher than 50° C. and lower than 90° C.Type: GrantFiled: November 8, 2013Date of Patent: June 23, 2020Assignee: AJINOMOTO CO., INC.Inventors: Hidetsugu Nakazawa, Hiroyuki Sato, Yuki Miyazawa, Susumu Shibahara, Sachiko Oka, Yumi Goto
-
Patent number: 10688044Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.Type: GrantFiled: March 15, 2019Date of Patent: June 23, 2020Assignee: Bryn Pharma, LLCInventors: Steven Hartman, Michelle Lobel, Matthew P Robben, Kenneth L. Dretchen, Michael Mesa
-
Patent number: 10688030Abstract: Suggested is a blend, comprising or consisting of: (a) at least one amino acid and/or at least one protein, and (b1) at least carboxylic acid alkyl ester and/or (b2) at least one diol, and optionally (c) at least at least one additional auxiliary agent.Type: GrantFiled: September 23, 2016Date of Patent: June 23, 2020Assignee: Symrise AGInventors: Adelino Nakano, Carolina Lourenco
-
Patent number: 10682302Abstract: Disclosed are compositions and methods for their use that can be used individually or in combination. The compositions have the ability to treat a wide range of skin and skin conditions, and particularly men's skin.Type: GrantFiled: February 9, 2018Date of Patent: June 16, 2020Assignee: Mary Kay Inc.Inventors: Ricky Mendoza, Barbara Durkee, Greg Norman, Geetha Kalahasti
-
Patent number: 10682316Abstract: The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.Type: GrantFiled: November 22, 2016Date of Patent: June 16, 2020Assignee: Nova Southeastern UniversityInventors: Mutasem Rawas-Qalaji, Ousama Rachid, Keith John Simons, Estelle Simons, Enrique Nieves
-
Patent number: 10675269Abstract: The present invention provides a composition comprising a synergistic combination of melatonin, valerenic acid and carnosic acid. The composition may be used in the treatment and prevention of several different disorders including inflammatory conditions, sleep disorders and anxiety. The invention also relates to several dosage forms which are suitable for the delivery of the claimed composition to subjects in need of treatment therewith.Type: GrantFiled: January 17, 2017Date of Patent: June 9, 2020Assignee: TRINUTRA LTD.Inventors: Yoram Sela, Mor Zeilkha, Itschak Lamensdorf
-
Patent number: 10675355Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: GrantFiled: December 29, 2014Date of Patent: June 9, 2020Assignees: VAR2 PHARMACEUTICALS APS, ZYMEWORKS INC.Inventors: James R. Rich, John Babcook, Ali El-Salanti, Mads Daugaard, Madeleine Dahlback, Bradley J. Hedberg, Geoffrey C. Winters, Alexander L. Mandel, Elyse Marie Josée Bourque, Tom Han Hsiao Hsieh
-
Patent number: 10669543Abstract: Compositions and methods to prevent, inhibit or treat aveolar or periodontal bone loss, enhance bone regeneration, prevent, inhibit or treat peri-implantitis or periodontitis, e.g., periodontitis or peri-implantitis associated with bone loss, or to prevent, inhibit or treat osteoarthritis are provided.Type: GrantFiled: January 15, 2016Date of Patent: June 2, 2020Assignee: University of Iowa Research FoundationInventors: Liu Hong, Brad A. Amendt, Aliasger K. Salem, Satheesh Elangovan, Gustavo Avila Ortiz, Thad Sharp
-
Patent number: 10669522Abstract: Methods for increasing the stability of, or protecting, labile components, such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium, are described. Stability of the labile compound is increased either, by derivatization or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule or by the use of sequestering agents. Encapsulation can provide controlled release of the susceptible compound being protected. These methods may improve or extend the storage conditions, the shipping and handling of media compositions comprising the labile compounds at room temperature rather than at lower temperatures, thereby decreasing shipping costs.Type: GrantFiled: February 7, 2012Date of Patent: June 2, 2020Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Richard Fike, Bruce Branchaud, Shawn Barrett
-
Patent number: 10668110Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.Type: GrantFiled: December 21, 2017Date of Patent: June 2, 2020Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Laura Fabbri, Fabrizio Salomone
-
Patent number: 10660855Abstract: The present invention relates to a process of producing a nano-CBD liposome system comprises: (i) preparing a dispersal phase by dissolving CBD in an ethanol solvent in a ratio between mass of CBD:volumn of ethanol solvent as 8:10 by a stirrer at a speed of 300 to 500 rpm and simultaneously heating to a temperature ranging from 40 to 60° C. within 4 to 8 hours; (ii) preparing a liposome carrier consisting of lecithin, olive oil in a ratio by mass of 1:3 mixed in a themostatic bath at a temperature from 40 to 60° C. to ensure that lecithin completely dissolves in oil, stirring homogeneously; (iii) adding the carrier to the dispersal phase in a ratio by mass of 40:60, continuing heating the dispersal phase to a temperature ranging from 40 to 60° C., stirring at a speed of 800 to 1000 rpm for 1 to 2 hours; (iv) cooling the resulting mixture to 25° C. and injecting one volumn of distilled water between 1 and 1.Type: GrantFiled: August 11, 2019Date of Patent: May 26, 2020Inventor: Hai Nam Lai
-
Patent number: 10661095Abstract: Disclosed is the use of copper cysteamine nanoparticles for use in photodynamic cancer therapy. The disclosed methods of treatment utilize microwave radiation as a means for activating the copper cysteamine photosensitizer.Type: GrantFiled: August 25, 2016Date of Patent: May 26, 2020Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wei Chen, Lun Ma
-
Patent number: 10653757Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.Type: GrantFiled: July 20, 2012Date of Patent: May 19, 2020Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael R. Yeaman, John E. Edwards, Jr., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, Jr.
-
Patent number: 10653796Abstract: The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.Type: GrantFiled: October 11, 2016Date of Patent: May 19, 2020Assignee: Universität HeidelbergInventors: Philipp Uhl, Max Sauter, Uwe Haberkorn, Walter Mier, Gert Fricker
-
Patent number: 10646504Abstract: Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs. The blended compositions are generally characterized as being able to efficiently deliver polynucleotides to target cells and by their ability to enhance the expression of such polynucleotides and the production of functional proteins by target cells.Type: GrantFiled: October 10, 2018Date of Patent: May 12, 2020Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Lianne Smith, Michael Heartlein, Braydon Charles Guild
-
Patent number: 10647968Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.Type: GrantFiled: September 10, 2012Date of Patent: May 12, 2020Assignees: Tsinghua University, Beijing Protgen Ltd.Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
-
Patent number: 10647785Abstract: The invention provides highly concentrated chitosan-nucleic acid polyplex compositions and dispersions, and methods for producing the compositions and dispersions. Methods of mixing the chitosan-nucleic acid polyplexes include an inline mixing of chitosan solution and nucleic acid solution, followed by further concentrating the dispersion of chitosan-nucleic acid polyplexes, optionally with an aggregation inhibitor. Further provides are methods for altering the diameter of chitosan-nucleic acid polyplexes.Type: GrantFiled: December 20, 2017Date of Patent: May 12, 2020Assignee: ENGENE, INC.Inventors: Eric Hsu, Carlos Fleet, Anthony Cheung, Jun Gao
-
Patent number: 10639278Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.Type: GrantFiled: October 22, 2014Date of Patent: May 5, 2020Assignee: Lipella Pharmaceuticals, Inc.Inventors: Jonathan H. Kaufman, Michael B. Chancellor
-
Patent number: 10639304Abstract: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.Type: GrantFiled: May 1, 2017Date of Patent: May 5, 2020Inventor: Ayyappan K. Rajasekaran
-
Patent number: 10633681Abstract: The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) and cannabichromenic acid (CBCA) in different ratios. The apparatus comprises: (i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (CBGA), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) or cannabidiolic acid (CBDA) and cannabichromenic acid.Type: GrantFiled: January 26, 2018Date of Patent: April 28, 2020Assignee: Teewinot Technologies LimitedInventors: Robert Winnicki, Marc Donsky, Mingyang Sun, Richard Peet
-
Patent number: 10634685Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.Type: GrantFiled: October 2, 2017Date of Patent: April 28, 2020Assignees: The UAB Research Foundation, Fundacao Oswaldo CruzInventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
-
Patent number: 10632072Abstract: The present disclosure provides systems and methods for the continuous production of liposomes. An example method includes (a) mixing a solution of lipid and organic solvent from one or more containers to create an organic solvent-lipid solution, (b) providing the organic solvent-lipid solution to a first inlet of an injection port at a first flow rate, wherein the first inlet is in fluid communication with a first conduit, (c) providing an aqueous solution to a second inlet of the injection port at a second flow rate, wherein the second inlet is influid communication with a second conduit, wherein the first conduit is positioned concentrically within the second conduit at an outlet of the injection port, and wherein the first conduit extends through the outlet of the injection port, and (d) mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes.Type: GrantFiled: March 18, 2016Date of Patent: April 28, 2020Assignee: University of ConnecticutInventors: Antonio Costa, Diane J. Burgess
-
Patent number: 10627364Abstract: Method for interfacing an integrated circuit with a biological ion channel, the integrated circuit being at least partially disposed within an electrolytic solution and including an amplifier and one or more electrodes on a surface thereof, includes forming one or more microwells proximate the one or more electrodes, applying a lipid membrane over the integrated circuit proximate the microwells, and placing a further electrode in the electrolytic solution proximate the lipid membrane on a side opposite the integrated circuit. A biological ion channel interface is also provided.Type: GrantFiled: October 8, 2014Date of Patent: April 21, 2020Assignee: The Trustees of Columbia University in the City of New YorkInventors: Kenneth L. Shepard, Jacob Rosenstein, Siddharth Ramakrishnan, Jared Roseman
-
Patent number: 10624850Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: April 27, 2018Date of Patent: April 21, 2020Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 10624852Abstract: Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.Type: GrantFiled: April 9, 2018Date of Patent: April 21, 2020Assignee: The University of North Carolina at Chapel HillInventors: Leaf Huang, Jun Li
-
Patent number: 10617672Abstract: A composition comprising liposomes comprising a lipid layer defining an internal aqueous compartment, an anthracycline drug entrapped in the internal aqueous phase and mitomycin C prodrug incorporated into the lipid layer is described.Type: GrantFiled: October 14, 2016Date of Patent: April 14, 2020Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
-
Patent number: 10617642Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: GrantFiled: March 8, 2013Date of Patent: April 14, 2020Assignee: Pacira Pharmaceuticals, Inc.Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
-
Patent number: 10617682Abstract: Embodiments relate to compositions comprising a prochlorperazine compound and a nasal carrier, including methods for formulating such compositions for pharmaceutical applications, for example, for treating or reducing the incidence of migraine headaches. Additional embodiments relate to articles comprising a prochlorperazine compound and a nasal carrier, including use of such articles as nasal drops or nasal sprays. Further embodiments relate to methods for using such articles, for example, for treating or reducing the incidence of migraines.Type: GrantFiled: May 31, 2018Date of Patent: April 14, 2020Assignee: Roseman University of Health SciencesInventor: Venkata Kashyap Yellepeddi